Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
Partner Joel Wallace shared his insight on the updated guidelines from the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) on running clinical trials and the potential effects of the COVID-19 pandemic on those trials.
The U.S. Food and Drug Administration (FDA) issued a guidance document today outlining its procedures for conducting clinical trials of investigational products in view of the worldwide COVID-19 outbreak.
On April 2, join USPTO officials and Arent Fox Partner Marylee Jenkins, Former Chair of the ABA-IPL Section and USPTO’s Patent Public Advisory Committee (PPAC), for the “Ask the USPTO: The Future of Artificial Intelligence” panel.
Arent Fox LLP is pleased to announce the expansion of its Patent practice and Life Sciences group with the addition of Counsels Daniel C. Stelter and Laurence H. Posorske, Ph.D. Mr. Stelter joins the firm’s San Francisco office, while Mr. Posorske joins Arent Fox in Washington, DC.
The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.
China’s rise as an economic superpower has been driven by the rapid pace of technological innovation, as evidenced by the recent surge in Chinese patent filings, patent grants, and patent enforcement actions.
Lost in the proceedings that have occupied our collective attention these last few months was the passage of the omnibus “Further Consolidated Appropriations Act, 2020,” which became law in late December and kept our country operating (at least for the near term).
New bipartisan legislation has been introduced to Congress that would authorize US Customs and Border Protection (CBP) to seize imported merchandise that infringes design patents at the US border.
Latinvex has once again rated Arent Fox as one of the best law firms in the world for companies with business operations in Latin America. In particular, the Latin America-focused business publication recognized the firm for its leading litigation, patent, and trademark counseling.
Arent Fox Intellectual Property Partner Marylee Jenkins has served as a member of the Patent Public Advisory Committee for the US Patent and Trademark Office since January 2013 and as Chair since December 2016.
On September 24, Administrative Patent Judges Jameson Lee, Thomas L. Giannetti, and Garth D. Baer of the U.S. Patent and Trademark Office found for Acronis, Inc., in a patent challenge against Realtime Data, LLC.
Arent Fox Patent Practice Group Leader Rich LaCava will be co-presenting at the Silicon Valley Association of General Counsel All Hands Meeting on November 19, 2019 in Santa Clara, California.
IP Partner Pamela M. Deese is a featured speaker at the Brand Protection Summit, co-hosted by CounterFind and Warner Music Group on November 7th, 2019 in New York.
Twenty-five Arent Fox LLP practices have been recognized in the 2020 “Best Law Firms” rankings that are published annually by US News & World Report and Best Lawyers.